Thanks to the efforts of Charles Wira, MD, associate professor of emergency medicine and principal investigator for SIREN (Strategies to Innovate Emergency Care Clinical Trials Network), and research associate Vanessa Zuniga, SIREN’S project director, Yale School of Medicine is now the second site for the Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial (KESETT) allowed to enroll nationwide.
SIREN aims to improve health outcomes by identifying effective treatments in the earliest stages of care. KESETT is testing whether adding ketamine to levetiracetam treats benzodiazepine-refractory seizures better than standard care alone.